Reports Q1 revenue $9.98M, consensus $8.67M. “In the first quarter, we continued to advance our business priorities and our pipeline of oncology therapeutics. We were pleased to share additional human imaging data that continue to validate the potential of MT1-MMP as a novel cancer target and demonstrate the positive properties of our Bicycle Radioconjugate molecules for radiopharmaceutical use,” said Bicycle Therapeutics (BCYC) CEO Kevin Lee. “Our work to develop zelenectide pevedotin for various Nectin-4 associated cancers continues to progress, as we recently initiated our Phase 1/2 Duravelo-3 trial for NECTIN4 gene-amplified breast cancer and remain on track for dose selection in our Phase 2/3 Duravelo-2 trial for metastatic urothelial cancer in the second half of this year. Additionally, with new members on our leadership team, Board of Directors and Clinical Advisory Board, and expected financial runaway extending to the second half of 2027, we remain focused on continuing to execute our strategy and make meaningful advances for patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Promising Imaging Data and Future Trials Support Buy Rating for Bicycle Therapeutics
- Bicycle Therapeutics Reveals Promising Imaging Data at AACR
- Bicycle Therapeutics: Buy Rating Backed by Promising Clinical Developments and Strategic Positioning
- Bicycle Therapeutics Announces Key Leadership Changes
- Bicycle names Pierre Legault chairman, Eric Westin chief medical officer